
|Videos|April 15, 2021
Selecting a PARP Inhibitor for Front Line Maintenance in Advance Ovarian Cancer
Author(s)Rebecca Previs, MD
Dr. Rebecca Previs discusses the role of PARP inhibitors in first line maintenance therapy in advanced ovarian cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
3
Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer
4
Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma
5






























































